Company / EPS (Diluted)
Neurocrine Biosciences EPS (Diluted) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
$2.47
FY2025
5-year range
$0.39 / $4.16
FY2021-FY2025
Trend
+58.3%
vs FY2024
Sector context
#21 of 204
Health Care
What the data says
Among 204 Health Care companies, Neurocrine Biosciences is in the top 10% for eps (diluted). EPS (Diluted) has fluctuated over the past 10 years, ranging from $-1.63 in FY2018 to $4.16 in FY2022.
Based on SEC 10-K filings.
2.47 in FY2025 with a 5-year CAGR of +62.2%. Top quartile in the Health Care sector.
Improved from $0.92 to $2.47 over the past 2 years.
Health Care sector context is included.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- -16.0%
- 5-Year CAGR
- +62.2%
- 10-Year CAGR
- -
Sector benchmark
Top 10% in Health CareTop 10% of 204This company $2.47 Sector average -$0.98
▼
+352.1% above sector average
Key checks
Key Insights
- In FY2025, eps (diluted) increased 58.3% year-over-year.
- Ranks #21 out of 204 companies in the Health Care sector.
- Peak eps (diluted) was recorded in FY2022.
- Lowest eps (diluted) in the period was in FY2018.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $2.47 | +58.3% |
| FY2024 | $1.56 | +69.6% |
| FY2023 | $0.92 | -77.9% |
| FY2022 | $4.16 | +966.7% |
| FY2021 | $0.39 | +77.3% |
| FY2020 | $0.22 | +113.6% |
| FY2019 | -$1.62 | +0.6% |
| FY2018 | -$1.63 | -55.2% |
| FY2017 | -$1.05 | -29.6% |
| FY2016 | -$0.81 | -17.4% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026